Meeting
2015 ASCO Annual Meeting
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
Authors
Claudia Pauligk
Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany
Claudia Pauligk , Andrea Tannapfel , Johannes Meiler , Kim Barbara Luley , Hans-Georg Kopp , Nils Homann , Ralf Dieter Hofheinz , Harald Schmalenberg , Stephan Probst , Georg Martin Haag , Matthias Egger , Dirk M. Behringer , Jan Stoehlmacher , Nicole Prasnikar , Andreas Block , Jorg Trojan , Michael Koenigsmann , Wolff Schmiegel , Elke Jäger , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01216644
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4016)
DOI
10.1200/jco.2015.33.15_suppl.4016
Abstract #
4016
Poster Bd #
125
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
First Author: Claudia Pauligk
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2013 Gastrointestinal Cancers Symposium
A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC).
First Author: Raquel Castellanos
Poster
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Hongli Li